Pharmacogenetics of Warfarin: Development of a Dosing Algorithm for Brazilian Patients

A dosing algorithm including genetic (VKORC1 and CYP2C9 genotypes) and nongenetic factors (age, weight, therapeutic indication, and cotreatment with amiodarone or simvastatin) explained 51% of the variance in stable weekly warfarin doses in 390 patients attending an anticoagulant clinic in a Brazilian public hospital. The VKORC1 3673G>A genotype was the most important predictor of warfarin dose, with a partial R(2) value of 23.9%. Replacing the VKORC1 3673G>A genotype with VKORC1 diplotype did not increase the algorithm`s predictive power. We suggest that three other single-nucleotide polymorphisms (SNPs) (5808T>G, 6853G>C, and 9041G>A) that are in strong linkage disequilibrium (LD) with 3673G>A would be equally good predictors of the warfarin dose requirement. The algorithm`s predictive power was similar across the self-identified ""race/color"" subsets. ""Race/color"" was not associated with stable warfarin dose in the multiple regression model, although the required warfarin dose was significantly lower (P = 0.006) in white (29 +/- 13 mg/week, n = 196) than in black patients (35 +/- 15 mg/week, n = 76).

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

CNPq Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)

Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)

Swiss Bridge Foundation

Swiss Bridge Foundation

Financiadora de Estudos e Projetos (FINEP)

Financiadora de Estudos e Projetos (FINEP)

Associacao Beneficente Alzira Denise Hertzog Silva to the Laboratorio de Neurociencias

Associação Beneficente Alzira Denise Hertzog da Silva (ABADHS)

Universidade de São Paulo - FM-USP

Universidade de São Paulo - FM-USP